Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples
The authors solved the crystal structures of two anhydrous psilocybin polymorphs (Polymorphs A and B) by Rietveld refinement against laboratory and synchrotron PXRD supported by DFT, and used those structures together with the known Hydrate A to perform quantitative phase analysis of historical and recent samples. They demonstrate that all examined material from 1963–2021 is accounted for as mixtures of these three forms (notably a claimed “isostructural variant” is ~81% Polymorph A/19% Polymorph B), concluding no additional crystalline forms are required and recommending revision of certain patent characterisations.
Authors
- Nicholas Cozzi
Published
Abstract
Psilocybin {systematic name: 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate} is a zwitterionic tryptamine natural product found in numerous species of fungi known for their psychoactive properties. Following its structural elucidation and chemical synthesis in 1959, purified synthetic psilocybin has been evaluated in clinical trials and has shown promise in the treatment of various mental health disorders. In a recent process-scale crystallization investigation, three crystalline forms of psilocybin were repeatedly observed: Hydrate A, Polymorph A, and Polymorph B. The crystal structure for Hydrate A was solved previously by single-crystal X-ray diffraction. This article presents new crystal structure solutions for the two anhydrates, Polymorphs A and B, based on Rietveld refinement using laboratory and synchrotron X-ray diffraction data, and density functional theory (DFT) calculations. Utilizing the three solved structures, an investigation was conducted via Rietveld method (RM) based quantitative phase analysis (QPA) to estimate the contribution of the three different forms in powder X-ray diffraction (PXRD) patterns provided by different sources of bulk psilocybin produced between 1963 and 2021. Over the last 57 years, each of these samples quantitatively reflect one or more of the hydrate and anhydrate polymorphs. In addition to quantitatively evaluating the composition of each sample, this article evaluates correlations between the crystal forms present, corresponding process methods, sample age, and storage conditions. Furthermore, revision is recommended on characterizations in recently granted patents that include descriptions of crystalline psilocybin inappropriately reported as a single-phase `isostructural variant.' Rietveld refinement demonstrated that the claimed material was composed of approximately 81% Polymorph A and 19% Polymorph B, both of which have been identified in historical samples. In this article, we show conclusively that all published data can be explained in terms of three well-defined forms of psilocybin and that no additional forms are needed to explain the diffraction patterns.
Research Summary of 'Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples'
Introduction
Psilocybin is a zwitterionic tryptamine natural product found in numerous mushroom species and has been revisited as a clinical candidate for several psychiatric indications. Earlier literature and process-scale work reported multiple solid forms of synthetic psilocybin, including solvent solvates, a hydrate and an anhydrous form, and more recent crystallisation studies identified three reproducible crystalline phases referred to here as Hydrate A, Polymorph A and Polymorph B. A patent application described related powder X-ray diffraction (PXRD) observations but used the ambiguous terminology 'isostructural variant' and raised the possibility that minor differences in diffractograms from large-scale production reflected a distinct single phase rather than mixtures or processing artifacts. Sherwood and colleagues aimed to solve the crystal structures of the two anhydrous forms (Polymorphs A and B) using powder diffraction and computational methods, and then to apply Rietveld-method (RM) quantitative phase analysis (QPA) to a set of historical and contemporary bulk psilocybin PXRD data. The study sought to determine whether all published diffraction patterns could be explained by the three characterised forms, to assess correlations between crystal form, processing and storage, and to test whether the phases invoked in recent patent claims were in fact single phases or mixtures arising from drying and scale effects.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Author
- APA Citation
Sherwood, A. M., Kargbo, R. B., Kaylo, K. W., Cozzi, N. V., Meisenheimer, P., & Kaduk, J. A. (2022). Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples. Acta Crystallographica Section C Structural Chemistry, 78(1), 36-55. https://doi.org/10.1107/S2053229621013164
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.